Charles N II York, CFO and VP at Spyre Therapeutics, holds 277.75K shares in Day One Biopharmaceuticals (Ticker: DAWN), holds 34.79K shares in Spyre Therapeutics (Ticker: SYRE).

See the Hottest Stocks Based on Insider Trading >

Charles N II York
Spyre Therapeutics (SYRE)
CFO and VP

Not Ranked

Charles N II York has not reported sufficient informative transactions and therefore cannot be ranked.

Time Frame

1 Year

Compare to

No Benchmark

How are Insiders Ranked?

Insider Holdings

78.02%

DAWN

21.98%

SYRE

A breakdown of Charles N II York's holdings

See the Top Stocks by Insiders

Insider Roles

Day One Biopharmaceuticals
(DAWN)

COO, CFO AND SECRETARY

Spyre Therapeutics
(SYRE)

CFO and VP

Roles that Charles N II York holds in companies

See the Top Corporate Insiders

Most Profitable Insider Trade

Stock:

Spyre Therapeutics
(SYRE)

Rating:Informative Buy

Date:Dec 05, 2017 - Dec 05, 2018

Return:+71.00%

The most profitable trade made by Charles N II York

See the Latest Stocks Traded by Insiders

Charles N II York's Trading History

SYRE

Spyre Therapeutics

Dec 05, 2017

CFO and VP

Uninformative Buy

21.44K

$1.17M

DAWN

Day One Biopharmaceuticals

Feb 20, 2024

COO, CFO AND SECRETARY

Uninformative Buy

40.63K

$4.14M

List of latest transactions for each holding click on a transaction to see Charles N II York's performance on stock

See All Insider Trading from Today

Charles N II York insider profile FAQ

What is the percentage of profitable transactions made by Charles N II York?

The percentage of profitable transactions made by Charles N II York is ―.

What is the average return per transaction made by Charles N II York?

The average return per transaction made by Charles N II York is ―.

What stocks does Charles N II York hold?

Charles N II York holds: SYRE, DAWN stocks.

What was Charles N II York’s latest transaction?

Charles N II York latest transaction was an Uninformative Buy of $40.63K.

What was Charles N II York's most profitable transaction?

Charles N II York’s most profitable transaction was an Informative Buy of SYRE stock on December 5, 2017. The return on the trade was 71.00%.

What is Charles N II York's role in Spyre Therapeutics?

Charles N II York's role in Spyre Therapeutics is CFO and VP.

How can I follow the stock ratings of top corporate insiders?

Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.

Charles N II York Insider Profile

Charles N II York Spyre Therapeutics (SYRE)CFO and VP